Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 7/26/19 → 6/14/25 |
Funding
- AstraZeneca Pharmaceuticals AB: $86,785.00
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I/III Limited Disease Small-Cell Lung
- Arnold, Susanne (PI)